
==== Front
Croat Med J
Croat Med J
CMJ
Croatian Medical Journal
0353-9504
1332-8166
Croatian Medical Schools

CroatMedJ_65_0383
10.3325/cmj.2024.65.383
Case Report
Challenging pharmacotherapy management of a psychotic disorder due to a delicate pharmacogenetic profile and drug-drug interactions: a case report and literature review
Belančić et al: Challenging pharmacotherapy management of a psychotic disorder
Belančić Andrej 1 2
Pavešić Radonja Aristea 3 4
Ganoci Lana 5
Vitezić Dinko 1 2
Božina Nada 6
1 Department of Clinical Pharmacology, Clinical Hospital Centre Rijeka, Rijeka, Croatia
2 Department of Basic and Clinical Pharmacology with Toxicology, University of Rijeka, Faculty of Medicine, Rijeka, Croatia
3 Psychiatry Clinic, Clinical Hospital Centre Rijeka, Rijeka, Croatia
4 Department of Psychiatry and Psychological Medicine, University of Rijeka, Faculty of Medicine, Rijeka, Croatia
5 Division of Pharmacogenomics and Therapy Individualization, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia
6 Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
The last two authors equally contributed.
Correspondence to:
Andrej Belančić
Clinical Hospital Centre Rijeka
Krešimirova 42
51000 Rijeka, Croatia
andrej.belancic@uniri.hr
8 2024
65 4 383395
15 3 2024
26 7 2024
Copyright © 2024 by the Croatian Medical Journal. All rights reserved.
2024
https://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
This report presents challenging psychopharmacotherapy management of a psychotic disorder in a patient with a delicate pharmacogenetic profile and drug-drug interactions. A 31-year old woman diagnosed with schizophrenia in 2017 was referred by her psychiatrist to a clinical pharmacologist for interpretation of a pharmacogenetic test and advice regarding optimal psychopharmacotherapy. In spite of adherence to aripiprazole, olanzapine, risperidone, and levomepromazine, and rational anxiolytic therapy, she still experienced anxiety, anhedonia, loss of appetite, sleeping problems, and auditory hallucinations with commands to harm herself. Due to a lack of alternative therapeutic steps, low aripiprazole serum concentration, and a lack of explanation for pharmacotherapy unresponsiveness, pharmacogenetic testing was performed. The patient was defined as CYP2D6 *1/*1, CYP1A2 *1F/*1F, CYP3A4 *1/*1B, CYP3A5 *1/*3, and having increased activity of the enzymes UGT1A4 and UGT2B7, intermediate activity of ABCB1 transporter, and low activity of COMT. Carbamazepine was discontinued, aripiprazole was increased to a maximum of 30 mg/day orally with long-acting injection (400 mg monthly), and olanzapine was increased to a daily dose of 35 mg orally. These changes led to an optimal therapeutic drug concentrations and improved clinical status. At the last follow-up, the patient was without severe auditory hallucinations, became more engaged in daily life, had more interaction with others, had found a job, and even had started an emotional relationship. In psychiatry, pharmacogenetic testing is an important tool for guiding pharmacological therapy, particularly in patients with an unsatisfactory clinical response and a lack of alternative therapeutic steps for pharmacotherapy unresponsiveness.
==== Body
pmcPersonalized medicine is a steadily growing field whose value lies in the prediction of individual responses to drugs regarding effectiveness, safety profile, and pharmacokinetics. Yet, there are still disagreements on its therapeutic applicability. As 25%-50% of people do not respond normally to drug treatment and standard dosage, personalized medicine calls for the development of resources for clinicians and pharmacogenetic (PGx) dosing guidelines for medicines. This is especially important since about 90% of patients undergoing PGx testing are likely to achieve a clinically actionable result (1).

PGx may be particularly important in mental health. The Food and Drug Administration (FDA) identified approximately 20% of the 121 pharmacogenetics markers as useful for clinical practice concerning psychiatric medicines (2). Implementation of PGx helps the selected patients and their referring clinicians to attain therapeutic drug concentrations more quickly, which ensures a safe, efficacious, proactive, and cost-effective approach (3,4). In psychiatry, a prompt clinical response is highly preferred since those patients in acute states are mostly uncooperative and incapable of everyday functioning on their own. Most antipsychotics/antidepressants are metabolized by CYP3A4, CYP2D6, and CYP2C19 enzymes in the liver (5). Genetic variants that affect the functioning of these enzymes are widespread (62% of people across the globe), and are strongly interconnected with enzymatic activity. Therefore, CYP2D6 and CYP2C19 have been the focus of Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines on the clinical use of PGx in psychiatry (6-8).

Antipsychotic medications per se do not cure schizophrenia, but they can alleviate its symptoms and improve the patient’s quality of life. Before optimal antipsychotic medicines and doses are found, many patients frequently experience a trial-and-error phase marked by poorly managed symptoms and/or severe drug reactions (9,10). Antipsychotic medication response varies substantially between patients; hence, multiple trials are often required to identify the medication that is most effective and tolerable for each individual. Thus, PGx may serve as a valuable tool, especially in treatment-resistant schizophrenia (present in up to 30% of people with schizophrenia) or in cases complicated by unexplained adverse drug reactions (ADRs) (10-12).

As various prescribed or over-the-counter medicines, or dietary sources, and their interactions may act as inhibitors or inducers of cytochrome P450 gene, in psychotropic medication management a thorough medical history-taking is necessary. In the upcoming years, patients’ pharmacogenetics data are going to become more widely integrated into clinical practice and electronic health. Also, psychiatric-pharmacogeneticist-clinical pharmacologist multidisciplinarity is going to become even more essential (1), particularly in psychiatry, where patients are frequently managed by numerous medicines.

Here, we report on a challenging psychopharmacotherapy management of a psychotic disorder in a patient who, in spite of adherence to high doses of four concomitant antipsychotics, at first did not achieve clinical response (in terms of auditory hallucinations control) due to pharmacogenetic predisposition and class-D drug-drug interactions. This article highlights the importance of pharmacogenetics and multidisciplinarity in psychiatry.

Case description

A 31-year old female patient, diagnosed with schizophrenia in 2017, was referred by her psychiatrist to a clinical pharmacologist for interpretation of a pharmacogenetic test and advice regarding optimal psychopharmacotherapy. At the outpatient visit (November 2021), her chronic pharmacotherapy consisted of a long-acting injection of aripiprazole (400 mg i.m. monthly), aripiprazole (10 mg/day orally), olanzapine (10 + 0 + 15 mg/day orally), risperidone (2 + 0 + 2 mg/day orally), levomepromazine (25 mg/day per need orally), carbamazepine (400 mg in the morning orally), oxazepam (15-15-30 mg/day orally), alprazolam (0.5 mg in the morning orally), biperiden (per need orally), bisoprolol (5 mg in the morning orally), and metoclopramide (10 mg in the morning orally). Before this antipsychotic regimen (after non-response to two antipsychotics), an attempt with clozapine was also made; however, it had to be terminated due to side effects (predominantly tachycardia).

In spite of adherence to four antipsychotics and anxiolytic medications, she still experienced anxiety, anhedonia, loss of appetite, sleep problems, and auditory hallucinations with imperative commands to harm herself. Due to a lack of alternative therapeutic steps, low aripiprazole serum concentrations (190 nmol/L; reference range: 334-1115 nmol/L), and a lack of explanations for pharmacotherapy unresponsiveness, pharmacogenetic testing was performed. We tested polymorphisms in the genes of metabolic enzymes and drug transporters involved in the metabolism of drugs listed in the patient’s pharmacotherapy. They were primarily selected according to pharmacogenetic guidelines. Also, they were selected based on the literature data for variants that may have functionally significant effects on enzyme or transporter function, or had been investigated for association with interindividual variability in drug response, drug pharmacokinetics, or adverse drug reactions. Pharmacogenetic polymorphisms ABCB1 c.3435C>T (rs1045642), ABCG2 c.421C>A (rs2231142), COMT c.472G>A (rs4680), CYP1A2*1F (rs762551), CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057910), CYP2C19*2 (rs4244285), CYP2C19*17 (rs12248560), CYP2D6*3 (rs35742686), CYP2D6*4 (rs3892097), CYP2D6*6 (rs5030655), CYP2D6*9 (rs5030656), CYP2D6*10 (rs1065852), CYP2D6 *41 (rs28371725), CYP3A4*1B (rs2740574), CYP3A4*22 (rs35599367), CYP3A5*3 (rs776746), UGT1A4*2 (rs6755571), and UGT2B7 c.-161C>T (rs7668258) were genotyped with TaqMan SNP Genotyping Assays (Applied Biosystems, Foster City, CA, USA) on a 7500 Real-Time PCR System (Applied Biosystems), according to the manufacturer’s instructions. UGT1A4*3 (rs2011425) was genotyped with Custom TaqMan SNP Genotyping Assay (Applied Biosystems), as previously published (13). CYP2D6*5 gene deletion and CYP2D6 duplications were genotyped by long-range polymerase chain reaction (14), and confirmed with TaqMan CNV assays for exon 9 (Hs00010001_cn), intron 2 (Hs04083572_cn), and intron 6 (Hs04502391_cn) (Applied Biosystems), on a 7500 Real-Time PCR System (Applied Biosystems), according to the manufacturer’s instructions.

Therapeutic drug monitoring (TDM) analysis of aripiprazole, carbamazepine, olanzapine, and risperidone was performed by high-performance liquid chromatography (Shimadzu Corporation, Kyoto, Japan). Genotyping and TDM methods were implemented and validated for routine testing in an accredited laboratory at the University Hospital Centre Zagreb. Genotyping results and their corresponding phenotypes are shown in Table 1.

Table 1 Pharmacogenetic analysis report and pharmacotherapy

Gene - allele	Genotype	Phenotype	Substrate	Inducer	Inhibitor	
Enzymes						
COMT c.472G>A	A/A	poor enzyme activity				
CYP1A2 *1F	*1F/*1F	increased inducibility, which can result in ultrarapid metabolism in the presence of inducer	carbamazepine
metoclopramide olanzapine	carbamazepine		
CYP2C9 *2, *3	*1/*1	normal metabolizer	alprazolam	carbamazepine		
CYP2C19 *2, *17	*1/*1	normal metabolizer		carbamazepine		
CYP2D6 xN, *3, *4, *5, *6, *9, *10, *41	*1/*1	normal metabolizer	aripiprazole
fluphenazine
levomepromazine
metoclopramide
olanzapine
risperidone		fluphenazine metoclopramide levomepromazine	
CYP3A4 *1B, *22	*1/*1B	normal metabolizer	alprazolam
aripiprazole
bisoprolol
carbamazepine
metoclopramide
olanzapine
risperidone	carbamazepine		
CYP3A5 *3	*1/*3	CYP3A5 expressor
(intermediate metabolizer)	alprazolam
aripiprazole
carbamazepine
olanzapine
risperidone	carbamazepine		
UGT1A4 *2, *3	*3/*3	high enzyme activity	olanzapine	carbamazepine		
UGT2B7 c.-161C>T	T/T	substrate specific enzyme activity	carbamazepine	carbamazepine		
Transporters						
ABCB1 c.3435C>T	C/T	intermediate function	bisoprolol
metoclopramide
olanzapine
risperidone	carbamazepine	aripiprazole
bisoprolol	
ABCG2 c.421C>A	C/C	normal function	risperidone		aripiprazole	

The patient was defined as normal CYP2C19 (CYP2C19 *1/*1), CYP2D6 (CYP2D6 *1/*1), and CYP3A4 (CYP3A4 *1/*1B) metabolizer; CYP3A5 (CYP3A5 *1/*3) exspressor; and ultrarapid CYP1A2 (CYP1A2 *1F/*1F) metabolizer. She had also high activity of the enzyme UGT1A4 (UGT1A4 *3/*3) and of UGT2B7 for some substrates (UGT1A4 c.-161TT), intermediate activity of the ABCB1 transporter ABCB1 c.3435CT, and poor activity of COMT (COMT c.472AA). Based on these results, carbamazepine (strong CYP3A4 inducer) and risperidone were discontinued, and aripiprazole (substrate of CYP2D6 and CYP3A4) was increased to a maximum of 30 mg/day orally (with a long-acting injection of aripiprazole 400 mg monthly), and olanzapine was increased to a daily dose of 35 mg orally (75% higher than the approved daily dose). This regimen finally resulted in optimal therapeutic drug concentrations and an improved clinical status (Figure 1). At her last ambulatory check-up (two years after carbamazepine discontinuation), the patient was without severe auditory hallucinations, had become more engaged in daily life, had more interaction with others, had obtained a job, and even had started an emotional relationship. The antipsychotic therapy consisted of aripiprazole long-acting injection (400 mg i.m. monthly), aripiprazole (30 mg/day orally), olanzapine (15 + 0 + 20 mg/day orally), and fluphenazine (7.5 + 0 + 5 mg/day orally). The most recent Positive and Negative Syndrome Scale score was 67, specifically comprising positive 17/negative 17/cognitive or general psychopathology 33; while she was deemed moderately ill on the Clinical Global Impression scale (15).

Figure 1 Therapeutic drug monitoring (TDM) and clinical responses to pharmacogenetic-guided pharmacotherapy management.

Discussion

Here, we report on a patient with schizophrenia who did not adequately respond to applied pharmacotherapy and experienced side effects (Figure 1). In order to determine the influence of gene polymorphisms relevant to the metabolism and transport of the applied drugs, a pharmacogenetic analysis was performed.

The patient’s treatment was not effective despite the use of several antipsychotics. Among the possible causes are lower-than-expected concentrations of the administered drugs (primarily aripiprazole, olanzapine, and risperidone) due to, at least in part, pharmacogenetic predisposition and drug-drug-gene interactions. Pharmacogenetic analysis showed that the patient had normal or increased activity of phase-I (CYPs) and phase-II metabolic enzymes (UGTs), intermediate activity of the ABCB1 transporter, and low activity of COMT. In addition, her therapy included carbamazepine, a strong inducer of several enzymes and transporters. All of these factors contributed to treatment failure. The patient’s condition improved after discontinuing carbamazepine, replacing risperidone, and adjusting the dose according to the available guidelines and relevant literature.

Several points need to be discussed for a better understanding of this case. By translating the analyzed genotypes into phenotypes, we tried to clarify the background for treatment failure. Treatment personalization for patients experiencing treatment failure or ADRs requires an accurate estimation of enzyme activity.

Aripiprazole

The main enzymes involved in the metabolism of aripiprazole are CYP2D6 and CYP3A4, and their gene variants can modulate its pharmacokinetics and eventually dosing (16,17). Aripiprazole’s main metabolite, dehydro-aripiprazole (D-ARI), has similar properties as the parent drug but, according to some authors, even more potent effects (18,19).

The DPWG’s guidelines listed relevant interactions of the CYP2D6, CYP3A4, and CYP1A2 genes and antipsychotic drugs (20). Medications requiring dose adjustment in patents with the CYP2D6 genotype included aripiprazole and risperidone, among others (brexpiprazole, haloperidol, pimozide, and zuclopenthixol).

The FDA and DPWG issued recommendations to reduce the doses of aripiprazole and risperidone in CYP2D6 poor metabolizers. In CYP2D6 ultrarapid metabolizers, better options are treatment with an alternative drug instead of risperidone or dose titration by measuring concentrations of the active metabolite paliperidone (9-hydroxyrisperidone) (20-24). Additionally, an adjustment and re-evaluation of the applied dose are recommended in cases of polytherapy with interacting drugs (22,23,25-27). For example, in cases of concomitant administration of aripiprazole and CYP3A4 inhibitors, the dose should be a quarter of the normal dose. DPWG also pointed out that pre-emptive testing for CYP2D6 is not necessary for all patients, but the decision should be made on an individual basis.

Pharmacogenetic analysis showed that our patient was a CYP2D6 normal metabolizer, and this genotype did not require dose adjustment. However, a gene variant that may contribute to faster metabolism via CYP2D6 (rs5758550) was not included in our diagnostic panel (28,29). For a better prediction of enhanced CYP2D6 enzyme activity, variants rs5758550 and *2 should be included in the test panel (29). Haplotype-based (rs5758550 and rs16947) prediction of CYP2D6 activity was more accurate than the prediction based on variant CYP2D6*2A alone. However, according to Dinh et al (28), the “enhancer” single nucleotide polymorphism (SNP) played a modest role in the prediction of the CYP2D6 phenotype. It had a more pronounced effect on atomoxetine than on dextromethorphan, which suggested potential substrate dependency (28). According to in vitro data, CYP2D6*2 alleles and the “enhancer” SNP, taken together, predispose for a modestly higher formation of metabolites (28). This observation was not confirmed in vivo, and no enhanced effect was observed for the combination of CYP2D6*1 and the enhancer SNP (28).

Another enzyme significant for the metabolism of aripiprazole is CYP3A4. CYP3A4, in addition to CYP2D6, is included in the dehydrogenation pathway involved in the formation of metabolites. The relevance of the gene variants coding for metabolic enzymes (CYP2D6, CYP3A4, and CYP3A5) and the ABCB1 drug transporter for aripiprazole pharmacokinetics was confirmed in healthy volunteers (30).

The human CYP3A enzyme subfamily is involved in the metabolism of approximately 50% of drugs used in clinical practice. CYP3A4 is expressed in the liver and intestine, while CYP3A5 is found dominantly in extrahepatic tissues. Both enzymes often have the same substrates and exhibit significant variability in their activity. Moreover, variability in populations is very high (31). Their drug substrates also include some psychotropic drugs. Because they have similar structure, function, and substrates, the relative involvement of CYP3A4 and CYP3A5 in drug biotransformation is hard to distinguish (32).

Since CYP3A4 is highly inducible, the relevance of genetic analysis is controversial. Environmental factors such as food, smoking, and other concurrently administered drugs, such as azole compounds, antibiotics, antiepileptics, and cyclosporine, have a stronger role than genetic polymorphisms. For example, citrus fruits, especially grapefruit juice, significantly inhibit CYP3A4 already at the intestinal level, but also on the drug transporter, P-glycoprotein, all of which can increase the bioavailability of drug-substrates.

An active CYP3A5 enzyme is present in only 10% of white people. People who have at least one active CYP3A5*1 allele are called expressors. Most of the population are nonexpressors due to a frequent mutation within intron 3 (rs776746) that predisposes to a splicing defect and formation of a protein with no enzyme activity. The prevalence of nonexpressors differs across populations (33). Guidelines on dosing according to CYP3A5 have been published only for tacrolimus (34,35).

Data on the influence of CYP3A4 gene polymorphisms on the expression and function of the enzyme are inconsistent. Some studies associate the variant CYP3A4*1B (–392A>G, rs2740574) in the promoter region with increased CYP3A4 activity, which influences substrate drug metabolism. Others argue that increased CYP3A activity is the result of the presence of the CYP3A5*1 functional allele with which CYP3A4*1B is in strong linkage disequilibrium (LD). It is complex to distinguish which variant is more important for accelerated metabolism (36). A meta-analysis (37) found that kidney transplant patients with the CYP3A4 *1/*1 genotype needed lower doses of tacrolimus than carriers of CYP3A4*1B. Also, tacrolimus trough concentrations were higher in CYP3A4*1/*1 genotype carriers compared with CYP3A4*1B carriers. New CYP3A4 and CYP3A5 genotyping recommendations consider CYP3A4*1B to be associated with normal enzyme activity (38).

The most studied CYP3A4 polymorphisms are *20 (loss-of-function) and *22 (reduced function) alleles, which could predispose to higher concentrations of drugs (39,40). Carriage of CYP3A4*20 can lead to a higher AUC0-t of aripiprazole and a lower AUC0-t of D-ARI, which can result in increased aripiprazole concentrations (30). CYP3A4*22 affects the metabolism of quetiapine (41), but a correlation with the pharmacokinetic parameters of aripiprazole or D-ARI was not confirmed (30).

CYP3A5 has a less significant role in aripiprazole metabolism than CYP2D6 (30). Nonexpressors with genotype CYP3A5 *3/*3 have higher levels of aripiprazole than expressors, such as our patient, who had lower concentrations of substrate drugs.

The published results regarding CYP3A5 are ambiguous. One study in Japanese patients revealed no effect of CYP3A5 variability on the plasma levels of either aripiprazole or its active metabolite (42). Another study found lower values for D-ARI/aripiprazole ratio in nonexpressors (*3/*3) than in expressors (*1/*1 and *1/*3) (30). Besides, the authors also reported the relevance of the *1 variant for the development of ADRs, especially nausea and vomiting, which were conditional on aripiprazole AUC. Dizziness was more common in female carriers of the CYP3A5 *1/*1 genotype (30). The study also confirmed the relevance of CYP2D6 phenotype, ABCB1 C1236T gene variants, and sex for the pharmacokinetics of aripiprazole, and CYP2D6 and C1236T for D-ARI. The CYP2D6 phenotype and CYP3A5*3 gene variant were also found to modulate the D-ARI/aripiprazole ratio. The authors found sex, aripiprazole exposure, CYP3A5*3, and the CYP2D6 phenotype relevant for the development of ADRs (30).

CYP3A (3A4/5) gene variants may also have contributed to low drug concentrations of aripiprazole in our patient. Variants that increase CYP3A4/5/7 expression have been recently reported by the Collins group (43). According to their study (43), the expression of CYP3A4, CYP3A5, and CYP3A7 is controlled by a distal regulatory region (DRR). In addition, using reporter gene assays, variants rs115025140 and rs776744/rs746742 were associated with altered DRR transcriptional activity and higher expression of CYP3A4 and CYP3A5, respectively (43). In liver samples, rs115025140 variant was found to be associated with higher expression of CYP3A4 mRNA and protein, and rs776744/rs776742 with higher expression of CYP3A5 mRNA (43). Since rs115025140 is found only in the population of African descent, African American carriers of this variant who take statin therapy may have lower efficiency in reducing lipids, possibly due to accelerated metabolism of statins via the CYP3A4 enzyme (43). Variants rs776744 and rs776742 were also associated with reduced exposure to tacrolimus in Chinese patients (43). These data could be clinically relevant in predicting CYP3A4 and CYP3A5 activity in specific populations carrying these variants.

The variability in drug exposure may also be attributed to variability in drug transporter activity. Both aripiprazole and D-ARI seem to be substrates of the ATP-binding cassette sub-family B member 1 transporter (ABCB1), called P-glycoprotein (P-gp) (44). P-gp is an efflux transporter involved in the intestinal absorption, transfer across the blood-brain barrier, and excretion of several antipsychotics, modulating their disposition and bioavailability in the brain (14,30,45,46).

According to some studies, P-gp expression and function and, consequently, drug concentrations are modulated by the gene variant ABCB1 c.3435T>C (rs1045642). T/T genotype carriers having less duodenal expression of P-gp could have higher levels of drugs (47). But there are also opposite claims in the literature (48,49). Besides 3435T>C SNP, two other ABCB1 gene variants, c.2677T>G/A (rs2032582) and c.1236C>T (rs1128503), being in strong LD, have been related to aripiprazole pharmacokinetics in different studies. However, the results are still controversial and there are no dosage guidelines. For aripiprazole, carriers of variant ABCB1 alleles 2677T>G/A (rs2032582) and 3435T>C (rs1045642) had lower plasma concentrations (50). The pharmacokinetic parameters of aripiprazole and D-ARI were affected by the ABCB 1236C>T variants. Higher values for aripiprazole clearance, AUC0-t, and maximum serum concentration for D-ARI, were observed in C/C compared with T/T carriers (30). Others reported no differences between ABCB1 variants (42,51). P-gp shares many substrates with CYP3A enzymes and, like them, can be influenced by drug inducers or inhibitors. Often, compounds that induce or inhibit CYP3A4 have the same effect on P-gp, additionally modulating drug bioavailability and effectiveness (52).

As our patient’s genotype indicated intermediate P-gp activity, we cannot conclude on the influence of the ABCB1 polymorphism. However, P-gp induction by carbamazepine (resulting in a stronger efflux pump) could be relevant for a lower absorption of aripiprazole, thereby contributing to its lower concentration.

Risperidone

DPWG recommended risperidone dose adjustment related to the CYP2D6 genotype (20,21,24). A reduced dose is proposed for CYP2D6 poor metabolizers. For CYP2D6 ultrarapid metabolizers, it is recommended to choose an alternative drug or to titrate the dose in relation to the concentrations of the metabolite paliperidone (9-hydroxyrisperidone) (20,24). Additionally, the dose is to be adjusted and re-evaluated when the patient's therapy includes concomitant administration of CYP3A4 inhibitors and/or inducers or CYP2D6 inhibitors (25-27).

In our previous research, CYP2D6 normal/ultrarapid metabolizers (vs other) had lower exposure to risperidone, and ABCB1 “wild type” allele carriers had 4-fold lower odds of response (14). ABCB1 variants, c.1236C>T (rs1128503) and c.2677G>T/A (rs2032582), have been associated with the effectiveness of several antipsychotics such as risperidone, clozapine, and haloperidol (53).

In our patient, CYP3A4*1B/3A5*1 variants could have also contributed to the accelerated metabolism of risperidone. Although carbamazepine was discontinued, the concentrations of risperidone and its active metabolite were still very low. Therefore, we considered that the influence of genetic predisposition for increased metabolism by CYP3A was relevant, and risperidone was switched to fluphenazine.

Literature data for CYP3A5 variants are controversial. While one study showed that CYP3A5 *3 carriers had higher levels of risperidone, 9-hydroxyrisperidone, and active moiety than CYP3A5*1 carriers (54), two other studies did not confirm this for the CYP3A phenotype (14,55), possibly due to the small sample size.

We also analyzed the COMT polymorphism, since some COMT variants influence antipsychotic response. The rs9606186 variant was found to affect the efficacy of risperidone in male patients (56), while for rs165599, the association with risperidone’s impact on negative symptoms was observed (57). Our patient was homozygous for the variant allele COMT c.472G>A (p.Val158Met, rs4680), and variant allele A was found to be associated with a decreased response to risperidone (58).

Olanzapine

The enzymes involved in phase I of olanzapine metabolism are CYP1A2, CYP2D6, and CYP3A4, and those involved in phase II are glucuronidation enzymes UGT1A4 and UGT2B10 (59,60).

Although relevant for olanzapine biotransformation, many studies have not demonstrated the association of CYP2D6 activity and olanzapine plasma levels (59,61-63). This is probably due to the secondary role of this enzyme in olanzapine biotransformation. Therefore, there are no recommendations for dosing based on the CYP2D6 phenotype. The EMA and FDA recommend that in patients treated with CYP1A2 inhibitors, a lower starting dose is considered (64,65). In cases of concomitant therapy with CYP3A4 and ABCB1 inducers or inhibitors, an appropriate dose for the patient has to be determined (64). Important factors that can modulate the bioavailability and efficacy of CYP1A2 substrates include drug-drug interactions and environmental factors such as smoking and diet (caffeine consumption, cruciferous vegetables, polyamine hydrocarbons from grilled meat) (66). These factors have been shown to induce CYP1A2, while fluoroquinolone antibiotics and oral contraceptives have been shown to reduce it (67).

Among the genetic variants of CYP1A2, CYP1A2*1F (c. −163C>A, rs762551) SNP is the most well-studied. According to the Pharmacogenomics Knowledgebase, the CYP1A2*1F variant has been associated with an altered phenotype (68). Because of increased induction of expression, it contributes to an accelerated metabolism of substrate drugs (ultrarapid metabolism). However, this effect is conditional on the concomitant use of an inducer such as smoking or heavy coffee consumption (69). In white smokers, carriage of the CYP1A2 -163 AA genotype predisposed for increased caffeine metabolism, while this effect was not observed in non-smokers (70). Drugs can also act as CYP1A2 inducers. Omeprazole taken by non-smoking healthy carriers of CYP1A2 *1F/*1F genotype compared with those with CYP1A2 *1C/*1F genotype increased the induction of caffeine metabolism (71). The CYP1A2*1F variant has been associated with increased enzyme inducibility and consequently lower agomelatine (CYP1A2 substrate) exposure (72). The latter study also observed a significant inter-racial difference in the frequency of CYP1A2 gene variants (72).

In our case, the use of carbamazepine as an inducer could have turned our patient, an *1F/*1F carrier, into an ultrarapid metabolizer. In several studies, the CYP1A2*1F variant was associated with lower olanzapine concentrations (59,61,73), which implies that the presence of the CYP1A2*1F allele enhances the inducibility of the enzyme when concomitant therapy with inducers is used. Significantly lower olanzapine concentrations and, consequently, the ineffectiveness of olanzapine therapy, were observed in *1F carriers compared with *1/*1 carriers. DPWG and CPIC recommend no dose adjustment for olanzapine and CYP1A2 genotypes.

There are no data on the accelerated metabolism of antipsychotics associated with the variants CYP3A4*1B and CYP3A5*1, but some conflicting data are provided for olanzapine and non-function allele CYP3A5*3 (61,74). As discussed earlier for aripiprazole, new SNP variants in the DRR that alter transcriptional activity (not tested in this patient) could have contributed to faster metabolism of olanzapine (43). However, the significance of these variants for the white population is still unknown.

The main role in glucuronidation of olanzapine is played by the enzymes uridine diphosphate glucuronosyltransferase, UGT1A4 and UGT2B10 (59). Our patient was homozygous for the variant UGT1A4*3, which implies accelerated metabolism (46) and increased glucuronidation of olanzapine (75), resulting in lower concentrations of the drug.

Olanzapine is also a substrate of P-gp/ABCB1. Some authors have reported on the association between ABCB1 c.1236T>C (rs1128503) T allele and elevated exposure to olanzapine, resulting in a better response to treatment (46,76). In another study, ABCB1 rs3842 CC was associated with higher olanzapine exposure (61), while other gene variants were associated with variability in T1/2 (51). In our previous study in female schizophrenic patients, MDR1/ABCB1 G2677T carriers of the variant allele (T) had a better response to olanzapine (77).

We can conclude that in our patient, an accelerated metabolism due to CYP3A, CYP1A2, and UGT variants, together with the induction caused by carbamazepine, could have resulted in lower olanzapine concentrations.

Carbamazepine

Carbamazepine is a strong inducer of multiple enzymes (CYPs and UGTs) and P-gp/ABCB1 transporter (78). Carbamazepine may interact with psychotropic drugs (79,80). Enzyme induction accelerates drug metabolism, while induction of P-gp changes the bioavailability of drugs at several levels: in enterocytes, the blood-brain barrier (BBB), and renal tubules. Induction enhances the function of the efflux pump, which results in a lower bioavailability of drug substrates (in this case olanzapine, risperidone, and aripiprazole). Induction of the ABCB1 transporter by carbamazepine at the gastrointestinal level means an increased efflux pump in enterocytes, induction at the BBB means a weaker passage of drugs into the brain, while induction in the kidneys means increased excretion of the drug.

The overall effect of induction with carbamazepine is reduced bioavailability of substrate drugs, and reduced entry into the brain, resulting in ineffectiveness. The AUC of aripiprazole (70%-90%) significantly decreases with the use of carbamazepine (81-83). In patients treated with 400 mg/day of carbamazepine, olanzapine exposure was lower by 36%-71% compared with patients on monotherapy (84-88).

Carbamazepine also has an effect on risperidone. A decrease in risperidone active moiety by 1.4 and 1.8 was reported with concomitant carbamazepine therapy (89,90). Risperidone active moiety doubled, resulting in ADR in a patient after carbamazepine discontinuation (91). On the other hand, a case study reported on the treatment for rapid reversal of long-acting risperidone by carbamazepine in a patient who developed extrapyramidal symptoms. The treatment relied on induction of CYP3A4 activity, since patients on long-acting antipsychotics need more time to excrete the offending drug (92). The gene variants of the enzymes CYP3A and UGT2B7 can also modulate the pharmacokinetics of carbamazepine (93). In our patient, the influence of enhanced metabolism via CYP3A and UGT2B7 was also observed. With 400 mg/day, a carbamazepine concentration of 10.4 μmol/L was achieved, while the expected range is 17-50 μmol/L. Physiologically based pharmacokinetic modeling is proposed to estimate the potential of carbamazepine interactions (94).

Conclusions

We report on a complex case of a patient who had a pharmacogenetic predisposition for accelerated metabolism by several drug metabolizing enzymes (CYP3A5, CYP1A2, UGT1A4, UGT2B7). Concomitant therapy with carbamazepine as a strong enzyme inducer resulted in low concentrations of substrate drugs aripiprazole, risperidone, and olanzapine and an ineffective treatment.

The case shows that knowledge of pharmacogenetic predispositions along with careful evaluation of possible drug interactions can contribute to personalized and effective treatment of psychiatric patients. A multidisciplinary approach including a psychiatrist, clinical pharmacologist, and pharmacogeneticist is inevitable, especially today in the era of personalized and modern medicine.

Funding None.

Ethical considerations The patient's anonymity was carefully protected. Written consent for publication was obtained from the patient.

Declaration of authorship all authors conceived and designed the study; all authors acquired the data; all authors analyzed and interpreted the data; AB, LG, NB drafted the manuscript; APR, DV critically reviewed the manuscript for important intellectual content; all authors gave approval of the version to be submitted; all authors agree to be accountable for all aspects of the work.

Competing interests All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.
==== Refs
References

1 Butler MG Pharmacogenetics and psychiatric care: a review and commentary. J Ment Health Clin Psychol. 2018 2 17 24 10.29245/2578-2959/2018/2.1120 30556062
2 Hamilton SP The promise of psychiatric pharmacogenomics. Biol Psychiatry 2015 77 29 35 10.1016/j.biopsych.2014.09.009 25483343
3 van Schaik RHN Müller DJ Serretti A Ingelman-Sundberg M Pharmacogenetics in psychiatry: an update on clinical usability. Front Pharmacol 2020 11 575540 10.3389/fphar.2020.575540 33041820
4 Karamperis K Koromina M Papantoniou P Skokou M Kanellakis F Mitropoulos K Economic evaluation in psychiatric pharmacogenomics: a systematic review. Pharmacogenomics J 2021 21 533 41 10.1038/s41397-021-00249-1 34215853
5 Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018 Jan;51(1–02):9–62.
6 CPIC C. Clinical Pharmacogenetics Implementation Consortium (CPIC Web site)Available from: https://cpicpgx.org/guidelines/ . Accessed: September 28, 2023.
7 Adiukwu F Adesokun O Essien E Yalcin N Ransing R Nagendrappa S Pharmacogenetic testing in psychiatry: Perspective on clinical utility. Asian J Psychiatr 2023 86 103674 10.1016/j.ajp.2023.103674 37327563
8 Koopmans AB Braakman MH Vinkers DJ Hoek HW van Harten PN Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19. Transl Psychiatry 2021 11 141 10.1038/s41398-020-01129-1 33627619
9 Alchakee A Ahmed M Eldohaji L Alhaj H Saber-Ayad M Pharmacogenomics in psychiatry practice: the value and the challenges. Int J Mol Sci 2022 23 13485 10.3390/ijms232113485 36362270
10 Lally J Gaughran F Timms P Curran SR Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics. Pharm Genomics Pers Med 2016 9 117 29 10.2147/PGPM.S115741 27853387
11 Kam H, Jeong H. Pharmacogenomic biomarkers and their applications in psychiatry. genes. 2020 Nov 30;11(12):1445.
12 Yoshida K Müller DJ Pharmacogenetics of antipsychotic drug treatment: update and clinical implications. Mol Neuropsychiatry 2020 5 Suppl 1 1 26 32399466
13 Klarica Domjanović I Lovrić M Trkulja V Petelin-Gadže Ž Ganoci L Čajić I Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy. Br J Clin Pharmacol 2018 84 2106 19 10.1111/bcp.13646 29791014
14 Ganoci L Trkulja V Živković M Božina T Šagud M Lovrić M ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone. Prog Neuropsychopharmacol Biol Psychiatry 2021 104 110042 10.1016/j.pnpbp.2020.110042 32682874
15 Kay SR Fiszbein A Opler LA The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987 13 261 76 10.1093/schbul/13.2.261 3616518
16 Soria-Chacartegui P Villapalos-García G Zubiaur P Abad-Santos F Koller D Genetic polymorphisms associated with the pharmacokinetics, pharmacodynamics and adverse effects of olanzapine, aripiprazole and risperidone. Front Pharmacol 2021 12 711940 10.3389/fphar.2021.711940 34335273
17 Jukic MM Smith RL Haslemo T Molden E Ingelman-Sundberg M Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. Lancet Psychiatry 2019 6 418 26 10.1016/S2215-0366(19)30088-4 31000417
18 Citrome L Josiassen R Bark N Salazar DE Mallikaarjun S Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol 2005 45 89 93 10.1177/0091270004269870 15601809
19 Wood MD Scott C Clarke K Westaway J Davies CH Reavill C Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur J Pharmacol 2006 546 88 94 10.1016/j.ejphar.2006.07.008 16925992
20 Beunk L, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Guchelaar HJ, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics. Eur J Hum Genet EJHG. 2023 Mar 31.
21 Bank PCD Caudle KE Swen JJ Gammal RS Whirl-Carrillo M Klein TE Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group Clin Pharmacol Ther 2018 103 599 618 10.1002/cpt.762 28994452
22 FDA A. (aripiprazole). FDA (2014). Abilify (aripiprazole). Highlights of prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021436s041,021713s032,021729s024,021866s026lbl.pdf . Accessed: September 28, 2023.
23 FDA AM. FDA (2016). Abilify Maintena (aripiprazole). Highlights of prescribing information Available from: https://www.accessdata.fda. gov/drugsatfda_docs/label/2016/202971s008lbl.pdf. Accessed: September 28, 2023.
24 Swen JJ Nijenhuis M de Boer A Grandia L Maitland-van der Zee AH Mulder H Pharmacogenetics: from bench to byte–an update of guidelines. Clin Pharmacol Ther 2011 89 662 73 10.1038/clpt.2011.34 21412232
25 EMA R. EMA. (2008). Risperdal (risperidone). Available from: https://www.ema.europa.eu/en/documents/referral/risperdal-article-30-referral-annex-i-ii-iii-iv_en-0.pdf . Accessed: September 28, 2023.
26 FDA R. FDA. (2010). Risperdal (risperidone). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020588s046lbl.pdf. Accessed: September 28, 2023.
27 FDA P. FDA. (2022). Perseris (risperidone). (Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210655s010lbl.pdf. Accessed: September 28, 2023.
28 Dinh JC Boone EC Staggs VS Pearce RE Wang WY Gaedigk R The impact of the CYP2D6 “enhancer” single nucleotide polymorphism on CYP2D6 activity. Clin Pharmacol Ther 2022 111 646 54 10.1002/cpt.2469 34716917
29 Ray B Ozcagli E Sadee W Wang D CYP2D6 haplotypes with enhancer single-nucleotide polymorphism rs5758550 and rs16947 (*2 allele): implications for CYP2D6 genotyping panels. Pharmacogenet Genomics 2019 29 39 47 10.1097/FPC.0000000000000363 30520769
30 Belmonte C Ochoa D Román M Saiz-Rodríguez M Wojnicz A Gómez-Sánchez CI Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 polymorphisms on pharmacokinetics and safety of aripiprazole in healthy volunteers. Basic Clin Pharmacol Toxicol 2018 122 596 605 10.1111/bcpt.12960 29325225
31 Zanger UM Schwab M Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013 138 103 41 10.1016/j.pharmthera.2012.12.007 23333322
32 Tseng E Walsky RL Luzietti RA Harris JJ Kosa RE Goosen TC Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide). Drug Metab Dispos 2014 42 1163 73 10.1124/dmd.114.057000 24737844
33 Kuehl P Zhang J Lin Y Lamba J Assem M Schuetz J Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001 27 383 91 10.1038/86882 11279519
34 Lamba J Hebert JM Schuetz EG Klein TE Altman RB PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet Genomics 2012 22 555 8 10.1097/FPC.0b013e328351d47f 22407409
35 Birdwell KA Decker B Barbarino JM Peterson JF Stein CM Sadee W Clinical pharmacogenetics implementation consortium (cpic) guidelines for cyp3a5 genotype and tacrolimus dosing. Clin Pharmacol Ther 2015 98 19 24 10.1002/cpt.113 25801146
36 Werk AN Cascorbi I Functional gene variants of CYP3A4. Clin Pharmacol Ther 2014 96 340 8 10.1038/clpt.2014.129 24926778
37 Shi WL Tang HL Zhai SD Effects of the CYP3A4*1B Genetic polymorphism on the pharmacokinetics of tacrolimus in adult renal transplant recipients: a meta-analysis. PLoS One 2015 10 e0127995 10.1371/journal.pone.0127995 26039043
38 Pratt VM Cavallari LH Fulmer ML Gaedigk A Hachad H Ji Y CYP3A4 and CYP3A5 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase. J Mol Diagn JMD. 2023 25 619 29 10.1016/j.jmoldx.2023.06.008 37419245
39 Westlind-Johnsson A Hermann R Huennemeyer A Hauns B Lahu G Nassr N Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Clin Pharmacol Ther 2006 79 339 49 10.1016/j.clpt.2005.11.015 16580902
40 Wang D Guo Y Wrighton SA Cooke GE Sadee W Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 2011 11 274 86 10.1038/tpj.2010.28 20386561
41 van der Weide K van der Weide J The influence of the CYP3A4*22 polymorphism on serum concentration of quetiapine in psychiatric patients. J Clin Psychopharmacol 2014 34 256 60 10.1097/JCP.0000000000000070 24525658
42 Suzuki T Mihara K Nakamura A Kagawa S Nagai G Nemoto K Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit 2014 36 651 5 10.1097/FTD.0000000000000070 24682161
43 Collins JM Nworu AC Mohammad SJ Li L Li C Li C Regulatory variants in a novel distal enhancer regulate the expression of CYP3A4 and CYP3A5. Clin Transl Sci 2022 15 2720 31 10.1111/cts.13398 36045613
44 Wang JS Zhu HJ Donovan JL Yuan HJ Markowitz JS Geesey ME Aripiprazole brain concentration is altered in P-glycoprotein deficient mice. Schizophr Res 2009 110 90 4 10.1016/j.schres.2009.01.011 19239981
45 Wang JS Zhu HJ Markowitz JS Donovan JL DeVane CL Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl) 2006 187 415 23 10.1007/s00213-006-0437-9 16810505
46 Saiz-Rodríguez M Belmonte C Román M Ochoa D Jiang-Zheng C Koller D Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants. Basic Clin Pharmacol Toxicol 2018 123 474 85 10.1111/bcpt.13031 29723928
47 Hoffmeyer S Burk O von Richter O Arnold HP Brockmöller J Johne A Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000 97 3473 8 10.1073/pnas.97.7.3473 10716719
48 Kim RB Leake BF Choo EF Dresser GK Kubba SV Schwarz UI Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001 70 189 99 10.1067/mcp.2001.117412 11503014
49 Sakaeda T Nakamura T Horinouchi M Kakumoto M Ohmoto N Sakai T MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001 18 1400 4 10.1023/A:1012244520615 11697464
50 Rafaniello C Sessa M Bernardi FF Pozzi M Cheli S Cattaneo D The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. Pharmacogenomics J 2018 18 422 30 10.1038/tpj.2017.38 28719598
51 Koller D Belmonte C Lubomirov R Saiz-Rodríguez M Zubiaur P Román M Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects. J Psychopharmacol 2018 32 1212 22 10.1177/0269881118798605 30251598
52 Grymonprez M Carnoy L Capiau A Boussery K Mehuys E De Backer TL Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother 2023 9 722 30 10.1093/ehjcvp/pvad070 37791408
53 Vijayan NN Mathew A Balan S Natarajan C Nair CM Allencherry PM Antipsychotic drug dosage and therapeutic response in schizophrenia is influenced by ABCB1 genotypes: a study from a south Indian perspective. Pharmacogenomics 2012 13 1119 27 10.2217/pgs.12.86 22909202
54 Kang RH Jung SM Kim KA Lee DK Cho HK Jung BJ Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. J Clin Psychopharmacol 2009 29 272 7 10.1097/JCP.0b013e3181a289e0 19440082
55 Vandenberghe F Guidi M Choong E von Gunten A Conus P Csajka C Genetics-based population pharmacokinetics and pharmacodynamics of risperidone in a psychiatric cohort. Clin Pharmacokinet 2015 54 1259 72 10.1007/s40262-015-0289-8 26129906
56 Zhao QZ Liu BC Zhang J Wang L Li XW Wang Y Association between a COMT polymorphism and clinical response to risperidone treatment: a pharmacogenetic study. Psychiatr Genet 2012 22 298 9 10.1097/YPG.0b013e328358629a 22935916
57 Han J Li Y Wang X Potential link between genetic polymorphisms of catechol-O-methyltransferase and dopamine receptors and treatment efficacy of risperidone on schizophrenia. Neuropsychiatr Dis Treat 2017 13 2935 43 10.2147/NDT.S148824 29255361
58 Shi Y Li M Song C Xu Q Huo R Shen L Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patients. Transl Psychiatry 2017 7 e1170 10.1038/tp.2017.143 28696411
59 Söderberg MM Dahl ML Pharmacogenetics of olanzapine metabolism. Pharmacogenomics 2013 14 1319 36 10.2217/pgs.13.120 23930678
60 Korprasertthaworn P Polasek TM Sorich MJ McLachlan AJ Miners JO Tucker GT In vitro characterization of the human liver microsomal kinetics and reaction phenotyping of olanzapine metabolism. Drug Metab Dispos 2015 43 1806 14 10.1124/dmd.115.064790 26329789
61 Zubiaur P Soria-Chacartegui P Villapalos-García G Gordillo-Perdomo JJ Abad-Santos F The pharmacogenetics of treatment with olanzapine. Pharmacogenomics 2021 22 939 58 10.2217/pgs-2021-0051 34528455
62 Nozawa M Ohnuma T Matsubara Y Sakai Y Hatano T Hanzawa R The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Ther Drug Monit 2008 30 35 40 10.1097/FTD.0b013e31816336fd 18223460
63 Koller D Saiz-Rodríguez M Zubiaur P Ochoa D Almenara S Román M The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial. Br J Clin Pharmacol 2020 86 2051 62 10.1111/bcp.14300 32250470
64 EMA Z. EMA. (2009). Zalasta (olanzapine). Available from: https://www.ema.europa.eu/en/documents/product-information/zalasta-epar-product-infoinforma_en.pdf. Accessed: September 28, 2023.
65 FDA Z. FDA. (1996). Zyprexa (olanzapine). Highlights of prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020592s051,021086s030,021253s036lbl.pdf . Accessed: September 28, 2023.
66 Zhou SF Yang LP Zhou ZW Liu YH Chan E Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J 2009 11 481 94 10.1208/s12248-009-9127-y 19590965
67 Gunes A Dahl ML Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics 2008 9 625 37 10.2217/14622416.9.5.625 18466106
68 Thorn CF Aklillu E Klein TE Altman RB PharmGKB summary: very important pharmacogene information for CYP1A2. Pharmacogenet Genomics 2012 22 73 7 10.1097/FPC.0b013e32834c6efd 21989077
69 Djordjevic N Ghotbi R Jankovic S Aklillu E Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C>A polymorphism. Eur J Clin Pharmacol 2010 66 697 703 10.1007/s00228-010-0823-4 20390257
70 Sachse C Brockmöller J Bauer S Roots I Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999 47 445 9 10.1046/j.1365-2125.1999.00898.x 10233211
71 Han XM Ouyang DS Chen XP Shu Y Jiang CH Tan ZR Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. Br J Clin Pharmacol 2002 54 540 3 10.1046/j.1365-2125.2002.01686.x 12445035
72 Saiz-Rodríguez M Ochoa D Belmonte C Román M Vieira de Lara D Zubiaur P Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics. J Psychopharmacol 2019 33 522 31 10.1177/0269881119827959 30789308
73 Czerwensky F Leucht S Steimer W CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations. Ther Drug Monit 2015 37 152 60 10.1097/FTD.0000000000000119 25090458
74 Cabaleiro T López-Rodríguez R Ochoa D Román M Novalbos J Abad-Santos F Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. Hum Psychopharmacol 2013 28 205 14 10.1002/hup.2308 23559402
75 Haslemo T Loryan I Ueda N Mannheimer B Bertilsson L Ingelman-Sundberg M UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems. Clin Pharmacol Ther 2012 92 221 7 10.1038/clpt.2012.46 22713701
76 Skogh E Sjödin I Josefsson M Dahl ML High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. J Clin Psychopharmacol 2011 31 4 9 10.1097/JCP.0b013e318204d9e2 21192135
77 Bozina N Kuzman MR Medved V Jovanovic N Sertic J Hotujac L Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J Psychiatr Res 2008 42 89 97 10.1016/j.jpsychires.2006.10.002 17113599
78 Perucca E Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006 61 246 55 10.1111/j.1365-2125.2005.02529.x 16487217
79 de Leon J Santoro V D’Arrigo C Spina E Interactions between antiepileptics and second-generation antipsychotics. Expert Opin Drug Metab Toxicol 2012 8 311 34 10.1517/17425255.2012.660918 22332980
80 Spina E Perucca E Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia 2002 43 Suppl 2 37 44 10.1046/j.1528-1157.2002.043s2037.x 11903482
81 Citrome L Macher JP Salazar DE Mallikaarjun S Boulton DW Pharmacokinetics of aripiprazole and concomitant carbamazepine. J Clin Psychopharmacol 2007 27 279 83 10.1097/jcp.0b013e318056f309 17502775
82 Nakamura A Mihara K Nagai G Suzuki T Kondo T Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia. Ther Drug Monit 2009 31 575 8 10.1097/FTD.0b013e3181b6326a 19701114
83 Castberg I Spigset O Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service. Pharmacopsychiatry 2007 40 107 10 10.1055/s-2007-977715 17541885
84 Lucas RA Gilfillan DJ Bergstrom RF A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur J Clin Pharmacol 1998 54 639 43 10.1007/s002280050527 9860152
85 Olesen OV Linnet K Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Ther Drug Monit 1999 21 87 90 10.1097/00007691-199902000-00013 10051059
86 Linnet K Olesen OV Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication. Ther Drug Monit 2002 24 512 7 10.1097/00007691-200208000-00009 12142636
87 Skogh E Reis M Dahl ML Lundmark J Bengtsson F Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit 2002 24 518 26 10.1097/00007691-200208000-00010 12142637
88 Botts S Diaz FJ Santoro V Spina E Muscatello MR Cogollo M Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. Prog Neuropsychopharmacol Biol Psychiatry 2008 32 1453 8 10.1016/j.pnpbp.2008.04.018 18555573
89 Spina E Avenoso A Facciolà G Salemi M Scordo MG Giacobello T Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Monit 2000 22 481 5 10.1097/00007691-200008000-00019 10942191
90 Ono S Mihara K Suzuki A Kondo T Yasui-Furukori N Furukori H Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology (Berl) 2002 162 50 4 10.1007/s00213-002-1056-8 12107617
91 de Leon J Bork J Risperidone and cytochrome P450 3A. J Clin Psychiatry 1997 58 450 10.4088/JCP.v58n1010b 9375597
92 Fuchs PA Miller L Schiff M The use of carbamazepine to expedite metabolism of risperidone long-acting injection through induction of CYP3A4 in a patient with extrapyramidal symptoms. Am J Psychiatry 2018 175 579 80 10.1176/appi.ajp.2018.17121359 29869546
93 Iannaccone T Sellitto C Manzo V Colucci F Giudice V Stefanelli B Pharmacogenetics of carbamazepine and valproate: focus on polymorphisms of drug metabolizing enzymes and transporters. Pharmaceuticals. 2021 14 204 10.3390/ph14030204 33804537
94 Fuhr LM Marok FZ Hanke N Selzer D Lehr T Pharmacokinetics of the CYP3A4 and CYP2B6 inducer carbamazepine and its drug–drug interaction potential: a physiologically based pharmacokinetic modeling approach. Pharmaceutics 2021 13 270 10.3390/pharmaceutics13020270 33671323
